- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00350103
A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Using Two Different Titration Schemes
The purpose of this trial is to assess whether 400mg/day of lacosamide is effective in reducing pain caused by distal diabetic neuropathy. Two dose-escalation schemes for lacosamide will be used to further determine the efficacy of the "standard" scheme and to evaluate the efficacy and safety of a more rapid titration scheme. Subjects will be randomly assigned to one of three treatment groups. Subjects in two of the groups will receive lacosamide at a dose of 400mg/day, but different dose-escalation schemes will be used to reach this final dose. The third group of subjects will receive a placebo. Subjects will have a 2 in 3 (66 %) chance of getting lacosamide.
The maximum lacosamide dose in this trial will be 400mg/day. The maximum treatment duration will be 18 weeks, including a two-week Pre-Treatment Phase and a 12 weeks period on a stable dose of lacosamide or placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Monheim, Germany
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject has had symptoms of painful diabetic neuropathy for at least 6 months and has a diagnosis of diabetes mellitus (Type I or Type II).
Exclusion Criteria:
- Subject has previously participated in this trial or subject has previously been assigned to treatment in a trial of the drug under investigation in this trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lacosamide Standard Titration (ST)
Subjects had their dose titrated from 100 mg/day to 400 mg/day at weekly intervals of 100 mg.
Subjects in this treatment group reach their target dose of 400 mg/day 3 weeks after Visit 2. All subjects completing the Titration Phase enter a 12-week Maintenance Phase.
|
Other Names:
|
Experimental: Lacosamide Fast Titration (FT)
Subjects receive 200 mg/day LCM for the first 3 days, 300 mg/day for the next 4 days, and reach their target dose of 400 mg/day after 1 week.
They undergo sham titration for the remaining 3 weeks of the Titration Phase.
All subjects completing the Titration Phase enter a 12-week Maintenance Phase.
|
Other Names:
|
Placebo Comparator: Placebo
Subjects underwent sham titration for the entire Titration Phase.
All subjects completing the Titration Phase enter a 12-week Maintenance Phase
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Average Daily Pain Score From Baseline Week to the Last 4 Weeks of the Maintenance Phase
Time Frame: Last 4 weeks of Maintenance Phase, compared to the Baseline Week
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
The value reported below is calculated as a difference between the average of the last available 28 days of maintenance for participants completing the maintenance phase (or the last 28 days prior to discontinuation for participants who discontinued in the titration or maintenance phase) and the average of the Baseline week.
|
Last 4 weeks of Maintenance Phase, compared to the Baseline Week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Sustainable Pain Relief
Time Frame: From start of trial medication intake (Week 0) up to the last 4 weeks of the Maintenance Phase
|
Time to sustainable pain relief was defined as the time from Baseline to the first day on which there was a ≥1-point improvement over Baseline in the Likert pain score for those subjects for whom there was also ≥30% reduction in average daily pain score over the last 28 days of the Maintenance Phase as compared to Baseline.
|
From start of trial medication intake (Week 0) up to the last 4 weeks of the Maintenance Phase
|
Percentage of Subjects With >= 30% or >= 2-point Reduction of with-in Subject Change in Average Daily Pain Score From the Baseline Week to the Last 4 Weeks of the Maintenance Phase
Time Frame: Baseline week, last 4 weeks of the Maintenance Phase
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
|
Baseline week, last 4 weeks of the Maintenance Phase
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to Visit 3
Time Frame: Baseline week, Visit 3
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
|
Baseline week, Visit 3
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to Visit 4
Time Frame: Baseline week, Visit 4
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
|
Baseline week, Visit 4
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to Visit 5
Time Frame: Baseline week, Visit 5
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
|
Baseline week, Visit 5
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to Visit 6
Time Frame: Baseline week, Visit 6
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
|
Baseline week, Visit 6
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to Visit 7
Time Frame: Baseline week, Visit 7
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
|
Baseline week, Visit 7
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to Visit 8
Time Frame: Baseline week, Visit 8
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
|
Baseline week, Visit 8
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to the Titration Phase
Time Frame: Titration Phase (4 weeks), compared to the Baseline Week
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
The value reported below is calculated as a difference between the average of the titration phase and the average of the Baseline Week.
|
Titration Phase (4 weeks), compared to the Baseline Week
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to the Maintenance Phase
Time Frame: Maintenance Phase (12 weeks), compared to the Baseline Week
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
The value reported below is calculated as a difference between the average of the maintenance phase and the average of the Baseline Week.
|
Maintenance Phase (12 weeks), compared to the Baseline Week
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to the Treatment Phase
Time Frame: Treatment Phase (16 weeks), compared to the Baseline Week
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
The value reported below is calculated as a difference between the average of the treatment phase and the average of the Baseline Week.
|
Treatment Phase (16 weeks), compared to the Baseline Week
|
Within-subject Change in Average Daily Pain Score From the Baseline Week to the Last 4 Weeks of Maintenance Phase
Time Frame: Last 4 weeks of Maintenance Phase, compared to the Baseline Week
|
An 11-point Likert scale is used to assess the subject's average daily pain.
This scale is completed by the subject twice daily (once in the morning and once in the evening).
The subject rates his/her average pain over the last 12 hours, from 0 (no pain) to 10 (worst pain ever experienced).
The daily pain score is defined as the average score of those collected in the morning and evening.
A negative value indicates improvement from Baseline.
The value reported below is calculated as a difference between the average of the last available 28 days of maintenance for participants completing the maintenance phase (or the last 28 days prior to discontinuation for participants who discontinued in the titration or maintenance phase) and the average of the Baseline week.
|
Last 4 weeks of Maintenance Phase, compared to the Baseline Week
|
Within-subject Change From the Baseline Week to Visit 3 in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Baseline Week, Visit 3
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2.
|
Baseline Week, Visit 3
|
Within-subject Change From the Baseline Week to Visit 4 in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Baseline Week, Visit 4
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2.
|
Baseline Week, Visit 4
|
Within-subject Change From the Baseline Week to Visit 5 in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Baseline Week, Visit 5
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2.
|
Baseline Week, Visit 5
|
Within-subject Change From the Baseline Week to Visit 6 in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Baseline Week, Visit 6
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2.
|
Baseline Week, Visit 6
|
Within-subject Change From the Baseline Week to Visit 7 in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Baseline Week, Visit 7
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2.
|
Baseline Week, Visit 7
|
Within-subject Change From the Baseline Week to Visit 8 in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Baseline Week, Visit 8
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2.
|
Baseline Week, Visit 8
|
Within-subject Change From the Baseline Week to the Titration Phase in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Titration Phase (4 weeks), compared to the Baseline Week
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2. The value reported below is calculated as a difference between the average of the titration phase and the average of the Baseline Week.
|
Titration Phase (4 weeks), compared to the Baseline Week
|
Within-subject Change From the Baseline Week to the Maintenance Phase in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Maintenance Phase (12 weeks), compared to the Baseline Week
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2. The value reported below is calculated as a difference between the average of the maintenance phase and the average of the Baseline Week.
|
Maintenance Phase (12 weeks), compared to the Baseline Week
|
Within-subject Change From the Baseline Week to the Treatment Phase in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Treatment Phase (16 weeks), compared to the Baseline Week
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement in symptoms.
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2. The value reported below is calculated as a difference between the average of the treatment phase and the average of the Baseline Week.
|
Treatment Phase (16 weeks), compared to the Baseline Week
|
Within-subject Change From the Baseline Week to the Last 4 Weeks of Maintenance Phase in Daily Perception of Pain Interference With Subject's Sleep
Time Frame: Last 4 weeks of Maintenance Phase, compared to the Baseline Week
|
An 11-point Likert scale was used to assess the subject's sleep.
The subject rated how the pain had interfered with sleep over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A lower value on the scale indicates improvement in symptoms.
A negative change value indicates improvement from Baseline.
Baseline Week was defined as the average of pain interference scores at the last 7 days prior to Visit 2. The value reported below is calculated as a difference between the average of the last available 28 days of maintenance for participants completing the maintenance phase (or the last 28 days prior to discontinuation for participants who discontinued in the titration or maintenance phase) and the average of the Baseline week.
|
Last 4 weeks of Maintenance Phase, compared to the Baseline Week
|
Within-subject Change From the Baseline Week to Visit 3 in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Baseline Week, Visit 3
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
|
Baseline Week, Visit 3
|
Within-subject Change From the Baseline Week to Visit 4 in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Baseline Week, Visit 4
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
|
Baseline Week, Visit 4
|
Within-subject Change From the Baseline Week to Visit 5 in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Baseline Week, Visit 5
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
|
Baseline Week, Visit 5
|
Within-subject Change From the Baseline Week to Visit 6 in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Baseline Week, Visit 6
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
|
Baseline Week, Visit 6
|
Within-subject Change From the Baseline Week to Visit 7 in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Baseline Week, Visit 7
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
|
Baseline Week, Visit 7
|
Within-subject Change From the Baseline Week to Visit 8 in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Baseline Week, Visit 8
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
|
Baseline Week, Visit 8
|
Within-subject Change From the Baseline Week to the Titration Phase in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Titration Phase (4 weeks), compared to the Baseline Week
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
The value reported below is calculated as a difference between the average of the titration phase and the average of the Baseline Week.
|
Titration Phase (4 weeks), compared to the Baseline Week
|
Within-subject Change From the Baseline Week to the Maintenance Phase in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Maintenance Phase (12 weeks), compared to the Baseline Week
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
The value reported below is calculated as a difference between the average of the maintenance phase and the average of the Baseline Week.
|
Maintenance Phase (12 weeks), compared to the Baseline Week
|
Within-subject Change From the Baseline Week to the Treatment Phase in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Treatment Phase (16 weeks), compared to the Baseline Week
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
The value reported below is calculated as a difference between the average of the treatment phase and the average of the Baseline Week.
|
Treatment Phase (16 weeks), compared to the Baseline Week
|
Within-subject Change From the Baseline Week to the Last 4 Weeks of the Maintenance Phase in Daily Perception of Pain Interference With Subject's General Activity
Time Frame: Last 4 weeks of Maintenance Phase, compared to the Baseline Week
|
An 11-point Likert scale was used to assess the subject's general activity.
The subject rated how the pain had interfered with general activity over the past 12 hours, from 0 (no interference) to 10 (complete interference).
A negative value indicates improvement from Baseline.
The value reported below is calculated as a difference between the average of the last available 28 days of maintenance for participants completing the maintenance phase (or the last 28 days prior to discontinuation for participants who discontinued in the titration or maintenance phase) and the average of the Baseline week.
|
Last 4 weeks of Maintenance Phase, compared to the Baseline Week
|
Percentage of Days of Rescue Medication Use During the Treatment Phase
Time Frame: During the Treatment Phase (up to 16 weeks)
|
Percentage of days of rescue medication use was the number of days in the visit/trial phase with rescue medication use divided by the total number of days in the visit/trial phase times 100.
|
During the Treatment Phase (up to 16 weeks)
|
Within-subject Change From Baseline to Visit 8 in Subject's Quality of Life
Time Frame: Baseline, Visit 8
|
Quality of life was analyzed using the Short Form-36 (SF-36) Health Survey.
The SF-36 is a participant self-rated questionnaire which consists of 8 sub-scores ranging from 0-100 with higher scores indicating a better health state.
The sub-scores are: 1. Physical Functioning, 2. Role-Physical, 3. Bodily Pain, 4. General Health, 5. Vitality, 6. Social Functioning, 7. Role-Emotional, 8. Mental Health.
Items 1-4 contribute to the physical component Summary (PCS) score.
Items 5-8 contribute to the mental component summary (MCS) score.
The PCS and MCS were based on the standardized values of the 8 domains.
The maximum and minimum possible values for PCS and MCS is 0-100, where higher scores indicate good condition.
A positive change value indicates improvement from baseline.
As pre-specified in SAP, values were planned to be summarized and disclosed by placebo and LCM 400 mg/day (pooled) groups.
|
Baseline, Visit 8
|
Percentage of Patients With Categorized Patient's Global Impression of Change in Pain (PGIC) at Visit 8
Time Frame: Visit 8
|
The PGIC is a 7-point categorical rating scale in which the subject rates the change in his/her pain since starting trial medication.
Categories are as following: much worse, moderately worse, mildly worse, no change, mildly better, moderately better, much better.
As pre-specified in SAP, values were planned to be summarized and disclosed by placebo and LCM 400 mg/day (pooled) reporting groups.
|
Visit 8
|
Percentage of Patients With Categorized Satisfaction With Medications at Visit 8
Time Frame: Visit 8
|
Categories of satisfaction are as following: very satisfied, satisfied, neither satisfied/dissatisfied, dissatisfied, very dissatisfied, not applicable, not done (no data available).
|
Visit 8
|
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale Scores at Visit 8
Time Frame: Baseline, Visit 8
|
The MOS Sleep scale is used to assess the subject's quality of sleep.
The scale consists of 12 individual items categorized into two sleep problems indices (SPI I/II) and 5 subscales: sleep disturbance, sleep somnolence, snoring, short of breath (SoB) or headache, sleep adequacy.
Scores range from 0 to 100.
Sleep adequacy scale: High values indicate a high quality of sleep.
A positive change indicates improvement in quality of sleep.
All other Sleep Scales: Low values indicate a high quality of sleep.
A negative change indicates improvement in quality of sleep.
|
Baseline, Visit 8
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: UCB Cares, 001 844 599 2273 (UCB)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Pain
- Diabetic Neuropathies
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Anticonvulsants
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lacosamide
Other Study ID Numbers
- SP0874
- 2005-005788-27 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Painful Diabetic Neuropathy
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
WinSanTor, IncCompletedPeripheral Neuropathy | Painful Diabetic Neuropathy | Diabetic Neuropathies, PainfulCanada
-
Maastricht University Medical CenterCompletedPainful Diabetic Neuropathy | Diabetic Neuropathies, Painful | Neuralgia, DiabeticNetherlands
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
Nevro CorpRecruitingPainful Diabetic NeuropathyUnited States
-
Dartmouth-Hitchcock Medical CenterRecruitingPainful Diabetic NeuropathyUnited States
-
Duta Wacana Christian UniversityPT SOHO Global Health TbkUnknownPainful Diabetic NeuropathyIndonesia
-
Helixmith Co., Ltd.Completed
-
BioDelivery Sciences InternationalCompletedNeuropathy | Painful Diabetic Neuropathy | Diabetic NeuropathyUnited States
Clinical Trials on SPM 929
-
Alkermes, Inc.QPS Netherlands B.V.Completed
-
Alkermes, Inc.Terminated
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
University of California, San FranciscoCompletedVascular Diseases | Osteoarthritis | Peripheral Arterial Disease | Claudication | Vascular Calcification | Claudication, Intermittent | Vascular OcclusionUnited States
-
UCB PharmaCompletedDiabetic NeuropathyUnited States
-
UCB PharmaCompletedPartial Seizures With or Without Secondary GeneralizationGermany
-
University of North Carolina, Chapel HillMetagenics, Inc.; North Carolina Translational and Clinical Sciences InstituteCompleted
-
UCB PharmaCompletedDiabetic NeuropathiesUnited States
-
UCB PharmaCompletedEpilepsies, PartialUnited States